Investors



Back

Interim Report, Q2 and H1 2014

August 26, 2014

CORTENDO REPORTS RESULTS AND ACTIVITIES FOR THE Q2 AND H1 OF 2014

HIGHLIGHTS - H1’2014 AND POST PERIOD

  • First patient enrolled into the NormoCort™ Phase 3 SONICS trial - continued progress on trial implementation.The internal and external NormoCort development team has been further strengthened
  • Matthew Pauls recruited as new CEO – effective Aug 25
  • Strategic review to further strengthen focus on orphan drugs and metabolic disease
  • Net loss for the Group was SEK 8.6 (5.6) million in Q2’2014 (Q2’2013) and SEK 19.8 (9.7) million in H1’2014 (H1’2013), reflecting increased R&D activities
  • Cash and cash equivalents amounted to SEK 75.4 million, compared to SEK 31.6 million at 30 June 2013 and SEK 97.1 million at the end of December 2013
  • Cortendo is currently preparing for and is targeting an Initial Public Offering and listing on the Oslo Stock Exchange during Q4’2014

For the full report see attached pdf-file.

wrk0006.pdf







© 2020 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V16 03/2020

  • Ireland Address:
    Suite 206, Fitzwilliam Hall
    Fitzwilliam Place, Dublin 2, D02 T292
    Ireland
  • U.S. Address:
    900 Northbrook Drive, Suite 200
    Trevose, PA 19053
    United States

Phone: +1 610-254-9200
[email protected]

Privacy Statement
Compliance Program